Abstract
IN the search for compounds active against human immunodeficiency virus (HIV), we have found that members of a novel series of tetrahydro-imidazo[4,5,1-jk][l,4]-benzodiazepin-2(1H)-one and -thione (TIBO) derivatives inhibit the replication of HIV-1 (refs 1, 2), the main aetiological agent of AIDS, but not of HIV-2 (ref. 3), or of any other DNA or RNA viruses. In five cell systems, HIV-1 is inhibited by TIBO derivatives in nanomolar amounts, which are 104–105 times lower than the cytotoxic concentration. The unprecedented specificity of these compounds may be due to an interaction with a reverse transcriptase-associated process. By contrast, AZT (3′-azido-2′,3′-dideoxythymidine), which is used for the treatment of AIDS, and DDC (2′,3′-dideoxycytidine) and DDI (2′,3′-dideoxyinosine), whose clinical application is being assessed, inhibit both HIV-1 and HIV-2 at concentrations that, depending on the cell systems, are 2 to 4 orders of magnitude below their cytotoxic concentration5–8. TIBO-derivatives are new chemicals unrelated to any other antiviral agents. We believe that they are the most specific and potent inhibitors of HIV-1 replication studied so far.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Barré-Sinoussi, F. et al. Science 220, 868–871 (1983).
Gallo, R. C. et al. Science 224, 500–503 (1984).
Clavel, F. et al. Science 233, 343–346 (1986).
Balzarini, J. & Broder, S. in Clinical Use of Antiviral Drugs (ed. De Clercq, E.) 361–385 (Martinus Nijhoff. Boston, 1988).
Mitsuya, H. et al. Proc. natn. Acad. Sci. U.S.A. 82, 7096–7100 (1985).
Chu, C. K. et al. Biochem. Pharmac. 37, 3543–3548 (1988).
Pauwels, R. et al. J. virol. Meth. 20, 309–321 (1988).
De Clercq, E. Antiviral Res. 12, 1–20 (1989).
Janssen, P. A. J. et al. J. pharmacol. exp. Ther. 244, 685–693 (1988).
Pauwels, R. et al. J. virol. Meth. 16, 171–185 (1987).
Clavel, F. & Guétard, D. AIDS 1, 135–140 (1987).
Harada, S., Koyanagi, Y. & Yamamoto, N. Science 229, 563–566 (1985).
Nakashima, H. et al. J. virol. Meth. 26, 319–330 (1989).
Schols, D., Baba, M., Pauwels, R., Desmyter, J. & De Clercq, E. Proc. natn. Acad. Sci. U.S.A. 86, 3322–3326 (1989).
Dalgleish, A. G. et al. Nature 312, 763–767 (1984).
Baba, M. et al. Proc. natn. Acad. Sci. U.S.A. 85, 6132–6136 (1988).
Mitsuya, H. et al. Science 240, 646–649 (1988).
Schols, D., Baba, M., Pauwels, R. & De Clercq, E. J. AIDS 2, 10–15 (1989).
Schols, D., Pauwels, R., Baba, M., Desmyter, J. & De Clercq, E. J. gen. Virol. 70, 2397–2408 (1989).
Baba, M. et al. Antivir. Res. 9, 335–343 (1988).
Starcich, B. R. et al. Cell 45, 637–648 (1986).
Clavel, F. et al. Nature 324, 691–695 (1986).
Rey, M. et al. Virology 173, 258–267 (1989).
Franchini, G. et al. Nature 328, 539–543 (1987).
Balzarini, J. et al. Biochem. biophys. Res. Commun. 145, 269–276 (1987).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pauwels, R., Andries, K., Desmyter, J. et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343, 470–474 (1990). https://doi.org/10.1038/343470a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/343470a0
This article is cited by
-
R&D dynamics and scientific breakthroughs in HIV/AIDS drugs development: the case of Integrase Inhibitors
Scientometrics (2014)
-
A time-of–drug addition approach to target identification of antiviral compounds
Nature Protocols (2011)
-
Establishment of a high-throughput screening system for universal anti-HIV targets
Chinese Science Bulletin (2010)
-
Molecular docking studies on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1 NNRT inhibitors
Journal of Computer-Aided Molecular Design (2008)
-
Assessing ligand efficiencies using template-based molecular docking and Tabu-clustering on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and-thione (TIBO) derivatives as HIV-1RT inhibitors
Journal of Chemical Sciences (2008)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.